Results 301 to 310 of about 87,967 (330)

Xanthines and Phosphodiesterase Inhibitors

2016
Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug ...
Clive P. Page, Domenico Spina
openaire   +2 more sources

Inhibitors of phosphodiesterases in the treatment of cough

Respiratory Physiology & Neurobiology, 2018
A group of 11 enzyme families of metalophosphohydrolases called phosphodiesterases (PDEs) is responsible for a hydrolysis of intracellular cAMP and cGMP. Xanthine derivatives (methylxanthines) inhibit PDEs without selective action on their single isoforms and lead to many pharmacological effects, e.g.
Daniela Mokra, Anna Urbanova, Martin Kertys, Juraj Mokry   +3 more
openaire   +3 more sources

Phosphodiesterase inhibitors in psychiatric disorders

Psychopharmacology, 2023
Challenges in drug development for psychiatric disorders have left much room for the introduction of novel treatments with better therapeutic efficacies and indices. As a result, intense research has focused on identifying new targets for developing such pharmacotherapies.
Mohammad Amin, Sadeghi, Ehsan, Nassireslami, Mojtaba, Yousefi Zoshk, Yasaman, Hosseini, Kourosh, Abbasian, Mohsen, Chamanara   +5 more
openaire   +2 more sources

Disaggregatory action of phosphodiesterase inhibitors

Pharmacological Research Communications, 1981
Summary Papaverine and three hypotensive xanthines were shown to disaggregate platelet clumps in anaesthetized cats. The order of disaggregatory potency was: IMBX > papaverine > > aminophylline ≫ xantinol nicotinate. This effect was not associated with the release of prostacyclin. It is concluded that disaggregatory action of papaverine and xanthines
Ryszard J. Gryglewski, Marek Radomski, J. Świȩs   +2 more
openaire   +3 more sources

The new inotropic phosphodiesterase inhibitors

Archives Internationales de Physiologie et de Biochimie, 1984
Compounds with phosphodiesterase inhibitory activity stimulate myocardial contractility by increasing the intracellular cyclic AMP concentrations. They can also increase Ca2+ entry and inhibit Ca2+ sequestration by the sarcoplasmic reticulum. Xanthines produce bronchodilation with associated venous and arteriolar dilation. However, their use is limited
D El Allaf, Jean Carlier, Vincenzo D'Orio   +2 more
openaire   +3 more sources

Phosphodiesterase inhibitors in clinical urology

Expert Review of Clinical Pharmacology, 2013
To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic hyperplasia and symptoms of female sexual dysfunction (including arousal and orgasmic disorders), can be therapeutically approached by influencing the ...
Markus A. Kuczyk, Stefan Ückert, Matthias Oelke   +2 more
openaire   +3 more sources

Phosphodiesterase Inhibitors for Cognitive Enhancement

Current Pharmaceutical Design, 2005
An effective treatment for age-related cognitive deficits remains an unmet medical need. Currently available drugs for the symptomatic treatment of Alzheimer's disease or other dementias have limited efficacy. This may be due to their action at only one of the many neurotransmitter systems involved in the complex mechanisms that underlie cognition.
Ashok Tehim, Gregory M. Rose, Allen T. Hopper, M. De Vivo   +3 more
openaire   +3 more sources

The role of phosphodiesterase inhibitors in impotence

Expert Opinion on Investigational Drugs, 1997
Penile erection is mediated by nitric oxide (NO) and its second messenger cyclic guanosine monophosphate (cGMP). The activity of cGMP is modulated by the enzyme phosphodiesterase (PDE). The most important physiological isoform of the enzyme in the penis is PDE5.
openaire   +3 more sources

Targeting cancer with phosphodiesterase inhibitors

Expert Opinion on Investigational Drugs, 2009
For many cancers, there has been a shift from management with traditional, nonspecific cytotoxic chemotherapies to treatment with molecule-specific targeted therapies that are used either alone or in combination with traditional chemotherapy and radiation therapy.
Ralph T. Schermuly, Gamal-Andre Banat, Hossein Ardeschir Ghofrani, Norbert Weissmann, Rajkumar Savai, Friedrich Grimminger, Soni Savai Pullamsetti   +6 more
openaire   +3 more sources

Phosphodiesterase Inhibitors: History of Pharmacology

2011
The first pharmacological investigations of phosphodiesterase (PDE) inhibitors were developed with the clinical efficacies of drugs isolated from coffee, cacao and tea but only later their relevant ingredients were identified as xanthines that act as PDE.
Rolf Beume, Armin Hatzelmann, Hermann Tenor, Christian Schudt   +3 more
openaire   +3 more sources